206 research outputs found
Detection and optimization of suspension-free logic programs
AbstractIn recent years, language mechanisms to suspend, or delay, the execution of goals until certain variables become bound have become increasingly popular in logic programming languages. While convenient, such mechanisms can make control flow within a program difficult to predict at compile time, and therefore render many traditional compiler optimizations inapplicable. Unfortunately, this performance cost is also incurred by programs that do not use any delay primitives. In this paper, we describe a simple dataflow analysis for detecting computations where suspension effects can be ignored, and discuss several low-level optimizations that rely on this information. Our algorithm has been implemented in the jc system. Optimizations based on information it produces result in significant performance improvements, demonstrating speed comparable to or exceeding that of optimized C programs
CFA2: a Context-Free Approach to Control-Flow Analysis
In a functional language, the dominant control-flow mechanism is function
call and return. Most higher-order flow analyses, including k-CFA, do not
handle call and return well: they remember only a bounded number of pending
calls because they approximate programs with control-flow graphs. Call/return
mismatch introduces precision-degrading spurious control-flow paths and
increases the analysis time. We describe CFA2, the first flow analysis with
precise call/return matching in the presence of higher-order functions and tail
calls. We formulate CFA2 as an abstract interpretation of programs in
continuation-passing style and describe a sound and complete summarization
algorithm for our abstract semantics. A preliminary evaluation shows that CFA2
gives more accurate data-flow information than 0CFA and 1CFA.Comment: LMCS 7 (2:3) 201
Kidney and vascular function in adult patients with hereditary fructose intolerance
Objective: Previous studies have shown that patients with hereditary fructose intolerance (HFI) are characterized by a greater intrahepatic triglyceride content, despite a fructose-restricted diet. The present study aimed to examine the long-term consequences of HFI on other aldolase-B-expressing organs, i.e. the kidney and vascular endothelium. Methods: Fifteen adult HFI patients were compared to healthy control individuals matched for age, sex and body mass index. Aortic stiffness was assessed by carotid-femoral pulse wave velocity (cf-PWV) and endothelial function by peripheral arterial tonometry, skin laser doppler flowmetry and the endothelial function biomarkers soluble E-selectin [sE-selectin] and von Willebrand factor. Serum creatinine and cystatin C were measured to estimate the glomerular filtration rate (eGFR). Urinary glucose and amino acid excretion and the ratio of tubular maximum reabsorption of phosphate to GFR (TmP/GFR) were determined as measures of proximal tubular function. Results: Median systolic blood pressure was significantly higher in HFI patients (127 versus 122 mmHg, p = .045). Pulse pressure and cf-PWV did not differ between the groups (p = .37 and p = .49, respectively). Of all endothelial function markers, only sE-selectin was significantly higher in HFI patients (p = .004). eGFR was significantly higher in HFI patients than healthy controls (119 versus 104 ml/min/1.73m2, p = .001, respectively). All measurements of proximal tubular function did not differ significantly between the groups. Conclusions: Adult HFI patients treated with a fructose-restricted diet are characterized by a higher sE-selectin level and slightly higher systolic blood pressure, which in time could contribute to a greater cardiovascular risk. The exact cause and, hence, clinical consequences of the higher eGFR in HFI patients, deserves further study.</p
Interactive Parallelization of Embedded Real-Time Applications Starting from Open-Source Scilab & Xcos
International audienceIn this paper, we introduce the workflow of interactive parallelization for optimizing embedded real-time applications for multicore architectures. In our approach, the real-time applications are written in the Scilab high-level mathematical & scientific programming language or with a Scilab Xcos block-diagram ap-proach. By using code generation and code parallelization technol-ogy combined with an interactive GUI, the end user can map appli-cations to the multicore processor iteratively. The approach is eval-uated on two use cases: (1) an image processing application written in Scilab and (2) an avionic system modeled in Xcos. Using the workflow, an end-to-end model-based approach targeting multicore processors is enabled resulting in a significant reduction in devel-opment effort and high application speedup. The workflow de-scribed in this paper is developed and tested within the EU-funded ARGO project focused on WCET-Aware Parallelization of Model-Based Applications for Heterogeneous Parallel Systems
Implementing clinical trial data sharing requires training a new generation of biomedical researchers
Data sharing enhances the value of medical research and builds trust in clinical trials, but more biomedical researchers need to be trained in these approaches, which include meta-research, data science and ethical, legal and social issues
Hidden magnetism at the pseudogap critical point of a high temperature superconductor
The mysterious pseudogap phase of cuprate superconductors ends at a critical
hole doping level p* but the nature of the ground state below p* is still
debated. Here, we show that the genuine nature of the magnetic ground state in
La2-xSrxCuO4 is hidden by competing effects from superconductivity: applying
intense magnetic fields to quench superconductivity, we uncover the presence of
glassy antiferromagnetic order up to the pseudogap boundary p* ~ 0.19, and not
above. There is thus a quantum phase transition at p*, which is likely to
underlie highfield observations of a fundamental change in electronic
properties across p*. Furthermore, the continuous presence of quasi-static
moments from the insulator up to p* suggests that the physics of the doped Mott
insulator is relevant through the entire pseudogap regime and might be more
fundamentally driving the transition at p* than just spin or charge ordering.Comment: 26 pages, supplementary info include
Improved PCR based methods for detecting C9orf72 hexanucleotide repeat expansions
Due to the GC-rich, repetitive nature of C9orf72 hexanucleotide repeat expansions, PCR based detection methods are challenging. Several limitations of PCR have been reported and overcoming these could help to define the pathogenic range. There is also a need to develop improved repeat-primed PCR assays which allow detection even in the presence of genomic variation around the repeat region. We have optimised PCR conditions for the C9orf72 hexanucleotide repeat expansion, using betaine as a co-solvent and specific cycling conditions, including slow ramping and a high denaturation temperature. We have developed a flanking assay, and repeat-primed PCR assays for both 3′ and 5′ ends of the repeat expansion, which when used together provide a robust strategy for detecting the presence or absence of expansions greater than ∼100 repeats, even in the presence of genomic variability at the 3′ end of the repeat. Using our assays, we have detected repeat expansions in 47/442 Scottish ALS patients. Furthermore, we recommend the combined use of these assays in a clinical diagnostic setting
Efficacy and safety of D,L-3-hydroxybutyrate (D,L-3-HB) treatment in multiple acyl-CoA dehydrogenase deficiency
PURPOSE: Multiple acyl-CoA dehydrogenase deficiency (MADD) is a life-threatening, ultrarare inborn error of metabolism. Case reports described successful D,L-3-hydroxybutyrate (D,L-3-HB) treatment in severely affected MADD patients, but systematic data on efficacy and safety is lacking.METHODS: A systematic literature review and an international, retrospective cohort study on clinical presentation, D,L-3-HB treatment method, and outcome in MADD(-like) patients.RESULTS: Our study summarizes 23 MADD(-like) patients, including 14 new cases. Median age at clinical onset was two months (interquartile range [IQR]: 8 months). Median age at starting D,L-3-HB was seven months (IQR: 4.5 years). D,L-3-HB doses ranged between 100 and 2600 mg/kg/day. Clinical improvement was reported in 16 patients (70%) for cardiomyopathy, leukodystrophy, liver symptoms, muscle symptoms, and/or respiratory failure. D,L-3-HB appeared not effective for neuropathy. Survival appeared longer upon D,L-3-HB compared with historical controls. Median time until first clinical improvement was one month, and ranged up to six months. Reported side effects included abdominal pain, constipation, dehydration, diarrhea, and vomiting/nausea. Median D,L-3-HB treatment duration was two years (IQR: 6 years). D,L-3-HB treatment was discontinued in 12 patients (52%).CONCLUSION: The strength of the current study is the international pooling of data demonstrating that D,L-3-HB treatment can be effective and safe in MADD(-like) patients.</p
Natural History of Liver Disease in a Large International Cohort of Children with Alagille syndrome:Results from The GALA Study
BACKGROUND: Alagille syndrome (ALGS) is a multisystem disorder, characterized by cholestasis. Existing outcome data are largely derived from tertiary centers and real-world data are lacking. This study aimed to elucidate the natural history of liver disease in a contemporary, international, cohort of children with ALGS.METHODS: Multicenter retrospective study of children with a clinically and/or genetically confirmed ALGS diagnosis, born Jan-1997 - Aug-2019. Native liver survival (NLS) and event-free survival rates were assessed. Cox models were constructed to identify early biochemical predictors of clinically evident portal hypertension (CEPH) and NLS.RESULTS: 1433 children (57% male) from 67 centers in 29 countries were included. 10 and 18-years NLS rates were 54.4% and 40.3%. By 10 and 18-years, 51.5% and 66.0% of ALGS children experienced ≥1 adverse liver-related event (CEPH, transplant or death). Children (>6 and ≤12 months) with median total bilirubin (TB) levels between ≥5.0 and <10.0 mg/dL had a 4.1-fold (95% CI 1.6 - 10.8) and those ≥10.0 mg/dL had an 8.0-fold (95% CI 3.4 - 18.4) increased risk of developing CEPH compared with those <5.0 mg/dL. Median TB levels between ≥5.0 and <10.0 mg/dL and >10.0 mg/dL were associated with a 4.8 (95% CI 2.4 - 9.7) and 15.6 (95% CI 8.7 - 28.2) increased risk of transplantation relative to <5.0 mg/dL. Median TB <5.0 mg/dL were associated with higher NLS rates relative to ≥5.0 mg/dL, with 79% reaching adulthood with native liver (p<0.001).CONCLUSIONS: In this large international cohort of ALGS, only 40.3% of children reach adulthood with their native liver. A TB <5.0 mg/dL between 6-and-12-months of age is associated with better hepatic outcomes. These thresholds provide clinicians with an objective tool to assist with clinical decision-making and in the evaluation of novel therapies.</p
Prediction models for diagnosis and prognosis of covid-19: : systematic review and critical appraisal
Readers’ note This article is a living systematic review that will be updated to reflect emerging evidence. Updates may occur for up to two years from the date of original publication. This version is update 3 of the original article published on 7 April 2020 (BMJ 2020;369:m1328). Previous updates can be found as data supplements (https://www.bmj.com/content/369/bmj.m1328/related#datasupp). When citing this paper please consider adding the update number and date of access for clarity. Funding: LW, BVC, LH, and MDV acknowledge specific funding for this work from Internal Funds KU Leuven, KOOR, and the COVID-19 Fund. LW is a postdoctoral fellow of Research Foundation-Flanders (FWO) and receives support from ZonMw (grant 10430012010001). BVC received support from FWO (grant G0B4716N) and Internal Funds KU Leuven (grant C24/15/037). TPAD acknowledges financial support from the Netherlands Organisation for Health Research and Development (grant 91617050). VMTdJ was supported by the European Union Horizon 2020 Research and Innovation Programme under ReCoDID grant agreement 825746. KGMM and JAAD acknowledge financial support from Cochrane Collaboration (SMF 2018). KIES is funded by the National Institute for Health Research (NIHR) School for Primary Care Research. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care. GSC was supported by the NIHR Biomedical Research Centre, Oxford, and Cancer Research UK (programme grant C49297/A27294). JM was supported by the Cancer Research UK (programme grant C49297/A27294). PD was supported by the NIHR Biomedical Research Centre, Oxford. MOH is supported by the National Heart, Lung, and Blood Institute of the United States National Institutes of Health (grant R00 HL141678). ICCvDH and BCTvB received funding from Euregio Meuse-Rhine (grant Covid Data Platform (coDaP) interref EMR187). The funders played no role in study design, data collection, data analysis, data interpretation, or reporting.Peer reviewedPublisher PD
- …